Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Jun 02, 2021 6:24pm
108 Views
Post# 33315819

RE:Milestones from Q1 conference call for Q2 and rest of year

RE:Milestones from Q1 conference call for Q2 and rest of yearVery obvious where Shift Communications fits in.

Nice to see pieces coming together.


LithLover wrote:

In the second quarter, we're focused on the following goals. First, we're ramping up our marketing to target patients and families within our US Care Oncology network. Second, we are planning to launch broad-based social media marketing, with the launch of direct-to-consumer campaigns, for AVRT and Aristotle in key markets. And finally, we plan to close on the Care Oncology acquisition.

For the remainder of the year, we are planning a marketing campaign targeting B2B partners, including channel partners, and self-insured, and re-insureds. Second, we're targeting to launch employer pilot programs with innovators and early adopter employer groups. And third, we're planning multi-channel marketing with national B2B and B2C campaigns.

-----------------------------------
Here is the full transcript:

https://seekingalpha.com/article/4429384-stagezero-life-sciences-ltd-gnwsf-ceo-james-howard-tripp-on-q1-2021-results-earnings-call

 



<< Previous
Bullboard Posts
Next >>